# BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

> **NCT01512251** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 8 (actual)

## Conditions studied

- BRAF Mutant Metastatic Melanoma

## Interventions

- **DRUG:** BKM120 Combined with Vemurafenib (PLX4032)

## Key facts

- **NCT ID:** NCT01512251
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-09
- **Primary completion:** 2013-12-13
- **Final completion:** 2017-03-21
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01512251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01512251, "BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01512251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*